Here, we investigated the therapeutic efficacy of a treatment that combines active-specific tumor-cell vaccination with mGM-CSF-secreting D5 melanoma cells and an antibody-mediated depletion of MDSC in a model of murine D5-melanoma. The gene discussed is CSF2; the disease is melanoma.